Skip to main content
. 2014 Oct 14;20(38):13741–13755. doi: 10.3748/wjg.v20.i38.13741

Table 6.

Clinical trial of ramucirumab

Patient Phase Treatment n OS (mo) PFS (mo) RR DCR
Second-line treatment for advanced gastric cancer or GEJ adenocarcinoma (REGARD) III BSC 117 3.8 1.3 2.6% 23.1%
Ramucirumab 238 5.2 2.1 3.4% 48.7%

BSC: Best supportive care; DCR: Disease control rate; GFJ: Gastroesophageal junction; OS: Overall survival; PFS: Progression-free-survival; RR: Response rate.